FGF21 and metabolic dysfunction-associated steatotic liver disease: The observed downregulation of FGF-21 in livers of animals treated with semaglutide and PYY3-36 may provide a link between liver steatosis and inflammation [54], while advanced fibrotic stages of MASLD were not observed in the present study.